Pancreatic cancer

Showing 9 posts of 24 posts found.


Incyte to stop Jakafi pancreatic, colorectal cancer drug trials

February 11, 2016
Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer

Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …

Merck image

Late-stage failure for Merck and Threshold cancer drug

December 7, 2015
Research and Development, Sales and Marketing Merck, Pancreatic cancer, Threshold Pharmaceuticals, evofosfamide, late-stage failure, phase III, sarcoma

Merck and its development partner Threshold Pharmaceuticals say they will not pursue regulatory approval for evofosfamide in advanced soft tissue …


Scientists make possible pancreatic cancer discovery

November 18, 2015
Research and Development Pancreatic cancer

Cancer researchers say they have discovered a potential new method of treatment for pancreatic cancer that could improve survival rates.  …

Phase III trial

FDA approves new therapy for pancreatic cancer

October 30, 2015
Medical Communications, Sales and Marketing FDA, Pancreatic cancer

The FDA has approved drug a pancreatic cancer drug, Onivyde, which has produced significant overall survival rates in an international …


NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’

September 17, 2015
Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer

NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …

Astellas logo

Cancer Research UK and Astellas announce partnership

August 8, 2014
Medical Communications, Research and Development, Sales and Marketing Astellas, CRUK, Canncer, Pancreatic cancer

Cancer Research UK and its commercial arm, Cancer Research Technology (CRT) have announced they are joining forces with Astellas in …

Novartis Afinitor

Afinitor expands European licence

September 5, 2011
Sales and Marketing Afinitor, Novartis, Pancreatic cancer

Novartis’ Afinitor has made further strides in the EU with an approval for use in patients with advanced pancreatic neuroendocrine …

Amgen HQ

Amgen aims for oncology expansion and a wider denosumab license

January 12, 2011
Research and Development AMG- 479, AMG-386, Amgen, Cancer, Pancreatic cancer, denosumab, motasenib

Amgen is seeking to increase the use of its bone drug denosumab and further its reach into the oncology market, …

Latest content